REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 35.17 Billion KRW | 16.83% |
| 2022 | 30.1 Billion KRW | 13.91% |
| 2021 | 26.43 Billion KRW | -7.05% |
| 2020 | 28.43 Billion KRW | 18.46% |
| 2019 | 24 Billion KRW | 15.43% |
| 2018 | 20.79 Billion KRW | -4.11% |
| 2017 | 21.68 Billion KRW | 3.27% |
| 2016 | 21 Billion KRW | -4.09% |
| 2015 | 21.89 Billion KRW | 12.92% |
| 2014 | 19.39 Billion KRW | -15.8% |
| 2013 | 23.03 Billion KRW | 31.61% |
| 2012 | 17.49 Billion KRW | -5.2% |
| 2011 | 18.46 Billion KRW | -1.76% |
| 2010 | 18.79 Billion KRW | 17.35% |
| 2009 | 16.01 Billion KRW | 30.95% |
| 2008 | 12.22 Billion KRW | 63.91% |
| 2007 | 7.46 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 36.81 Billion KRW | 4.66% |
| 2024 Q2 | 36.31 Billion KRW | -1.37% |
| 2023 Q1 | 28.4 Billion KRW | -5.67% |
| 2023 FY | 35.17 Billion KRW | 16.83% |
| 2023 Q3 | 31.65 Billion KRW | -1.0% |
| 2023 Q4 | 35.17 Billion KRW | 11.14% |
| 2023 Q2 | 31.96 Billion KRW | 12.55% |
| 2022 Q4 | 30.1 Billion KRW | -5.3% |
| 2022 Q3 | 31.79 Billion KRW | 0.85% |
| 2022 FY | 30.1 Billion KRW | 13.91% |
| 2022 Q1 | 27.48 Billion KRW | 3.97% |
| 2022 Q2 | 31.52 Billion KRW | 14.72% |
| 2021 Q3 | 26.69 Billion KRW | -7.75% |
| 2021 Q2 | 28.94 Billion KRW | -4.15% |
| 2021 FY | 26.43 Billion KRW | -7.05% |
| 2021 Q1 | 30.19 Billion KRW | 6.18% |
| 2021 Q4 | 26.43 Billion KRW | -1.0% |
| 2020 FY | 28.43 Billion KRW | 18.46% |
| 2020 Q1 | 26.15 Billion KRW | 8.96% |
| 2020 Q2 | 30.35 Billion KRW | 16.03% |
| 2020 Q3 | 31.34 Billion KRW | 3.29% |
| 2020 Q4 | 28.43 Billion KRW | -9.29% |
| 2019 Q2 | 22.83 Billion KRW | 7.21% |
| 2019 Q3 | 22.71 Billion KRW | -0.52% |
| 2019 FY | 24 Billion KRW | 15.43% |
| 2019 Q4 | 24 Billion KRW | 5.67% |
| 2019 Q1 | 21.3 Billion KRW | 2.42% |
| 2018 Q2 | 21.83 Billion KRW | 2.16% |
| 2018 Q1 | 21.37 Billion KRW | -1.44% |
| 2018 Q4 | 20.79 Billion KRW | -6.3% |
| 2018 FY | 20.79 Billion KRW | -4.11% |
| 2018 Q3 | 22.19 Billion KRW | 1.65% |
| 2017 Q3 | 21.44 Billion KRW | 0.0% |
| 2017 FY | 21.68 Billion KRW | 3.27% |
| 2017 Q4 | 21.68 Billion KRW | 1.13% |
| 2017 Q1 | - KRW | -100.0% |
| 2016 Q4 | 21 Billion KRW | 0.0% |
| 2016 Q2 | 21.54 Billion KRW | 1.3% |
| 2016 FY | 21 Billion KRW | -4.09% |
| 2016 Q1 | 21.26 Billion KRW | -2.88% |
| 2015 Q4 | 21.89 Billion KRW | -6.8% |
| 2015 FY | 21.89 Billion KRW | 12.92% |
| 2015 Q3 | 23.49 Billion KRW | 4.52% |
| 2015 Q2 | 22.48 Billion KRW | 9.2% |
| 2015 Q1 | 20.58 Billion KRW | 6.16% |
| 2014 Q4 | 19.39 Billion KRW | -9.47% |
| 2014 Q3 | 21.42 Billion KRW | 3.59% |
| 2014 Q1 | 21.17 Billion KRW | -8.04% |
| 2014 Q2 | 20.67 Billion KRW | -2.36% |
| 2014 FY | 19.39 Billion KRW | -15.8% |
| 2013 Q1 | 26.73 Billion KRW | 52.78% |
| 2013 Q3 | 22.33 Billion KRW | -8.4% |
| 2013 Q4 | 23.03 Billion KRW | 3.1% |
| 2013 Q2 | 24.38 Billion KRW | -8.79% |
| 2013 FY | 23.03 Billion KRW | 31.61% |
| 2012 Q1 | 18.48 Billion KRW | 0.15% |
| 2012 Q3 | 16.74 Billion KRW | 9.19% |
| 2012 Q4 | 17.49 Billion KRW | 4.51% |
| 2012 FY | 17.49 Billion KRW | -5.2% |
| 2012 Q2 | 15.33 Billion KRW | -17.06% |
| 2011 Q2 | 22.32 Billion KRW | 5.13% |
| 2011 Q1 | 21.23 Billion KRW | 12.99% |
| 2011 Q3 | 19.14 Billion KRW | -14.22% |
| 2011 Q4 | 18.46 Billion KRW | -3.59% |
| 2011 FY | 18.46 Billion KRW | -1.76% |
| 2010 Q3 | 15.56 Billion KRW | -11.34% |
| 2010 FY | 18.79 Billion KRW | 17.35% |
| 2010 Q4 | 18.79 Billion KRW | 20.71% |
| 2010 Q2 | 17.55 Billion KRW | 0.0% |
| 2009 FY | 16.01 Billion KRW | 30.95% |
| 2008 FY | 12.22 Billion KRW | 63.91% |
| 2007 FY | 7.46 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 20.329% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 70.152% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 61.415% |
| HANDOK Inc. | 94.46 Billion KRW | 62.762% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -65.59% |
| Yuhan Corporation | 284.75 Billion KRW | 87.647% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 69.757% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -116.355% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 87.82% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -8.622% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 43.011% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -80.604% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -16.17% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 27.242% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 20.329% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -12.598% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 26.911% |
| JW Holdings Corporation | 147.58 Billion KRW | 76.166% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 58.432% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 86.545% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 66.843% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 34.766% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -30.293% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -8.197% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 67.954% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 20.329% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 81.353% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 85.437% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 66.843% |
| Yuhan Corporation | 284.75 Billion KRW | 87.647% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 71.922% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 43.252% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 86.462% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 66.843% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 55.81% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 28.419% |
| CKD Bio Corp. | 69.08 Billion KRW | 49.08% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 66.524% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 50.244% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 34.928% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 34.766% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 81.939% |
| Boryung Corporation | 189.8 Billion KRW | 81.467% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 38.104% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 43.011% |
| JW Lifescience Corporation | 23.39 Billion KRW | -50.336% |